Journals / Turkish Journal of Hematology / 2010 / Cilt: 27 - Sayı: 2

Kronik idiopatik myelofibrozis olgusunun kemik iliğinde kompleks sitogenetik bulgular

Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient

Pages
113–116
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The patient died shortly thereafter.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Chronic idiopathic myelofibrosis is a myeloproliferative disorder characterized by splenomegaly, myeloid metaplasia and reactive bone marrow fibrosis.
📊
Key Findings & Data:The frequency of clonal cytogenetic anomalies in this disease is the highest among its group, varying between 30 and 75%.
💡
Conclusion & Impact:The patient died shortly thereafter.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Chronic idiopathic myelofibrosis is a myeloproliferative disorder characterized by splenomegaly, myeloid metaplasia and reactive bone marrow fibrosis. Karyotype analysis of the bone marrow is an integral part of the diagnosis, especially as a discriminative tool in ruling out reactive conditions. The frequency of clonal cytogenetic anomalies in this disease is the highest among its group, varying between 30 and 75%. Among these, trisomy 1q, 20q-, 13q- and +8 are the most common aberrations. Here we report a 66-year-old male patient whose bone marrow biopsy revealed signs of chronic myeloproliferative changes and dysmegakaryopoiesis. He was administered hydroxyurea treatment, splenic radiotherapy and multiple transfusions. The patient worsened in the following months and the second bone marrow biopsy revealed myelofibrosis. Cytogenetic analysis of this bone marrow sample revealed a complex karyotype reported to be 46,XY,del(9) (q22q34),t(8;17;21)(q22;q21;q22)[23]/46,XY[2], with a previously undefined three-way translocation and deletion in chromosome 9. The patient died shortly thereafter.

Özet

Kronik idiopatik myelofibrozis, kronik myeloproliferatif hastalıklardandır ve splenomegali, myeloid metaplazi ve reaktif kemik iliği fibrozisi ile karakterizedir. Bu hastalıkların tanısında, özellikle de reaktif durumları ekarte etmek için kemik iliğinden kromozom analizi oldukça önemli bir araçtır. İdiopatik myelofibrozis, bu grup içerisinde en yüksek klonal sitogenetik anomali sıklığına sahiptir (%30-75). Trizomi 1q, 20q-, 13q- ve +8 en sık gözlenen anomalilerdendir. Bu yazımızda masif splenomegali ile başvuran 66 yaşında erkek olgunun bulguları sunulmaktadır. Olgunun kemik iliği biyopsisinde kronik myeloprolifera- tif değişiklikler ve dismegakaryopoez saptandı. Hidroksiüre tedavisi, splenik radyoterapi ve çok sayıda transfüzyon alan hastanın kliniği ilerleyen aylarda kötüleşti. Yapılan ikinci kemik iliği biyopsisisinde myelofibrozis gözlendi. Bu örneğin sitoge- netik incelemesi sonucu daha önce tanımlanmamış üç yollu bir translokasyon ve 9. kromozomda delesyon saptandı. Karyotipi 46,XY,del(9)(q22q34),t(8;17;21)(q22;q21;q22)[23]/46,XY[2] olarak belirlendi. Olgu kısa süre sonra kaybedildi.

🔖

Cite This Article

BALCI, T. B., YÜKSEL, M., YILMAZ, Z., ŞAHİN, F. İ. (2010). Kronik idiopatik myelofibrozis olgusunun kemik iliğinde kompleks sitogenetik bulgular. Turkish Journal of Hematology, Cilt: 27 - Sayı: 2, 113–116. https://ajindex.com/articles/412928

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Haferlach T, Bacher U, Kern W, Schnittger S, Haferlach C. The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers. Ann Hematol 2008;87:1-10
  2. Demory JL, Dupriez B, Fenaux P, Laï JL, Beuscart R, Jouet JP, Deminatti M, Bauters F. Cytogenetic studies and their prognostic significance in agnogenic myeloid metaplasia: a report on 47 cases. Blood 1988;72:855-9
  3. Ahmed A, Chang CC. Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis. Arch Pathol Lab Med 2006;130:1133-43
  4. Djordjevic V, Dencic-Fekete M, Jovanovic J, Bizic S, Jankovic G, Bogdanovic A, Cemerikic-Martinovic V, Gotic M. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients. Cancer Genet Cytogenet 2007;173:57-62
  5. Tefferi A, Mesa RA, Schroeder G, Hanson CA, Li CY, Dewald GW. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol 2001;113:763-71
  6. Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, Fiegl M, Simonitsch-Klupp I, Gisslinger H, Zojer N, Ludwig H. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia. Cancer 2006;107:2801-6
  7. Nand S, Stock W, Godwin J, Fisher SG. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Am J Hematol 1996;52:42-6
  8. Burkitt MJ, Raafat A. Nitric oxide generation from hydroxyurea: significance and implications for leukemogenesis in the management of myeloproliferative disorders. Blood 2006;107:2219-22
  9. McFarland JT, Kuzma C, Millard FE, Johnstone PA. Palliative irradiation of the spleen. Am J Clin Oncol 2003;26:178-83
  10. Tucker JD. Low-dose ionizing radiation and chromosome translocations: a review of the major considerations for human biological dosimetry. Mutat Res 2008;659:211-20
  11. Cornforth MN. Perspectives on the formation of radiation-induced exchange aberrations. DNA Repair (Amst) 2006;5:1182-91
  12. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica 2007;92:1389-98.